At NGGT, I lead AAV gene therapy programs across ophthalmology, metabolic, cardiometabolic, renal, and neurodegenerative diseases—from early discovery through FDA and CDE INDs, investigator-initiated trials, and Phase I–III studies.
I've integrated translational strategy, pharm/tox, regulatory filing, medical affairs, and clinical development to move programs through candidate nomination and key clinical inflection points. I formulate first-in-human and proof-of-concept trial strategies, lead regulatory interactions, and optimize study designs for stronger results, reduced cost, and shorter timelines.
I build and mentor multidisciplinary teams spanning R&D, Pharm/Tox, Medical Affairs, Clinical Operations, and Regulatory. My work is grounded in scientific rigor, data-driven decisions, productive challenge, and practical management of program risks, budgets, and cross-functional trade-offs.
Before NGGT, I developed neuroimmunology programs at NeuCyte and researched neurodegeneration, glial repair, and neuroinflammation at the University of Colorado, Penn State, and Johns Hopkins. I bring more than 20 years of translational medicine and clinical development experience, along with publications, patents, and deep scientific experience in neurology and gene therapy.
